Tempest Therapeutics Inc. (TPST)
0.92
-0.00 (-0.27%)
At close: Jan 14, 2025, 3:59 PM
0.92
0.16%
Pre-market Jan 15, 2025, 07:22 AM EST
undefined% (undefined)
| Bid | 0.91 |
| Market Cap | 40.09M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.6 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.92 |
| Volume | 809,940 |
| Avg. Volume (20D) | 3,136,634 |
| Open | 0.94 |
| Previous Close | 0.92 |
| Day's Range | 0.90 - 0.94 |
| 52-Week Range | 0.70 - 6.00 |
| Beta | undefined |
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 12, 2012
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TPST
Website https://www.tempesttx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for TPST stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 1315.35% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-10.5%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago ·
Source
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
